{"id":"atra-plus-6-mp-and-mtx","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Differentiation syndrome (ATRA syndrome)"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATRA (all-trans retinoic acid) induces differentiation of acute promyelocytic leukemia (APL) cells, particularly those with t(15;17) translocations, promoting maturation and apoptosis. 6-MP (6-mercaptopurine) and MTX (methotrexate) are antimetabolites that inhibit nucleotide synthesis and cell proliferation, providing additional cytotoxic activity. The combination leverages differentiation therapy with conventional chemotherapy for enhanced efficacy in hematologic malignancies.","oneSentence":"This combination uses ATRA to differentiate leukemic cells while 6-MP and MTX provide cytotoxic chemotherapy to eliminate rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:02.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT00866918","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-03-09","conditions":"Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm","enrollment":106},{"nctId":"NCT00482833","phase":"PHASE3","title":"Phase III Trial in Acute Promyelocytic Leukemia Patients","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2007-08","conditions":"Leukemia","enrollment":276},{"nctId":"NCT00003934","phase":"PHASE3","title":"Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-06","conditions":"Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Childhood Acute Promyelocytic Leukemia (M3)","enrollment":420},{"nctId":"NCT00962767","phase":"PHASE3","title":"Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-05","conditions":"Leukemia, Myelocytic, Acute","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arm B"],"phase":"phase_3","status":"active","brandName":"ATRA plus 6-MP and MTX","genericName":"ATRA plus 6-MP and MTX","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ATRA to differentiate leukemic cells while 6-MP and MTX provide cytotoxic chemotherapy to eliminate rapidly dividing cancer cells. Used for Acute promyelocytic leukemia (APL), Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}